Patient-based drug discovery's latest news
Ksilink grows and further develops
During the last months Ksilink has welcomed seven new scientists experts in cell biology, drug screening, and image and data mining. “We are happy to have now an outstanding team...
New publication in SLAS discovery
Our Internet site, www.ksilink.com, has had a complete makeover, working on "Travel and Health info" Keep in touch !
New strategic partnership to fight heart disease
On October 29th 2019, Ksilink has initiated two new strategic partnerships with the Biological Adaptation and Ageing research unit of the Institute of Biology Paris Seine...
Change in continuity: professor Alain Beretz appointed as new Ksilink chairman
On September 24th 2019, Ksilink Board of Directors appointed Professor Alain Beretz (on the left) as new Chairman of the Association, replacing Professor André Syrota (on the...
Come together cardiovascular disease
Ksilink organizes a come together in the field of patient based disease modeling for cardiovascular diseases. Prof Zimmermann from University of Göttingen and Dr. Kirchmeir...
Ksilink increases its computing capacity
Ksilink acquires one high performance GPU/TPU cluster from locally-based 2CRSI company to implement deep learning approaches to its drug discovery programs for cardiovascular and...
Press release – Collaboration with I-Stem on ASD and DM1
Ksilink initiates 2 new drug discovery programs on Muscular Dystrophy-1 (DM1) and Autism Spectrum Disorders (ASD) with its strategic partner I-Stem. Click here to download the...
Press release – Collaboration with Anagenesis on DMD
Together with Anagenesis Biotechnologies, Ksilink reachs first exit point in the field of Duchenne Muscular Disease. A major industrial Venture Fund invests into Anagenesis with...
Press release – Collaboration with LCSB on Parkinson’s disease
Ksilink teams up with the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg to develop drugs to treat Parkinson’s disease. Together they will...
